Status:
UNKNOWN
Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Hepatocellular carcinoma (HCC) is a common disease in East Asia. Less than 20% of newly diagnosed patients can undergo radical resection. For those with unresectable BCLC C stage, transarterial chemot...
Eligibility Criteria
Inclusion
- BCLC C stage with unresectable diseasehigh-recurrence risk factor;
- Child-Pugh A or B (7 score) liver function;
- Anticipated survival more than 3 moths
Exclusion
- Pregnant woman or sucking period;
- With other malignant cancer;
- Received anti-HCC therapy before this study
Key Trial Info
Start Date :
April 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04814030
Start Date
April 20 2021
End Date
December 30 2022
Last Update
April 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060